FDA OKs GE Healthcare's molecular imaging agent

09/21/2008 | AuntMinnie.com (free registration)

The FDA has cleared GE Healthcare's molecular imaging agent AdreView for use in diagnosing neuroblastoma in children and pheochromocytoma, a rare tumor that typically affects adults. AdreView is meant to complement CT, MRI and SPECT data, and is expected to be available in hospitals and imaging facilities throughout the U.S. within several weeks.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY